PROCEPT BioRobotics Announces New CPT Category I Code From The AMA For Aquablation Therapy To Treat Benign Prostatic Hyperplasia

PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association ("AMA") has established a new Current Procedural Terminology ("CPT") Category I code for transurethral waterjet resection of prostate tissue ("Aquablation therapy") to treat benign prostatic hyperplasia ("BPH").

 

In response to increased utilization of Aquablation therapy and strong evidence for its clinical outcomes, the AMA accepted PROCEPT BioRobotics' application for a Category I CPT code, which will replace the existing Category III CPT code starting January 1, 2026. In the meantime, U.S. hospitals and physicians performing Aquablation therapy procedures should continue to utilize the existing Category III code, 0421T.